Table 1 Treatment dose data for research dogs
R1 | R2 | R3 | ||
|---|---|---|---|---|
Infused activity (GBq) | 0.019 | 0.025 | 0.016 | |
Treatment days post-calibration | 10 | 10 | 10 | |
Volume of embolic (mL)* | 0.0011 | 0.0015 | 0.00094 | |
Delivery | ICA | MCA | PCA | |
Perfused fraction† | 1 | 0.61 | 0.26 | |
Single compartment dose (Gy) | 27.9 | 66.5 | 73 | |
Dosimetry method | MicroCT | MicroCT | MicroCT | |
Perfused territory | Mean dose (Gy) | 14.0 | 30.9 | 73.2 |
Max dose (Gy) | 4484.0 | 10,231.0 | 8864.0 | |
V20 | 19.1 | 57.9 | 87.1 | |
V30 | 12.8 | 33.4 | 78.0 | |
V50 | 6.0 | 12.4 | 67.5 | |
V60 | 4.1 | 8.1 | 44.8 | |
V80 | 2.1 | 3.9 | 32.4 | |
V100 | 1.2 | 2.3 | 23.2 | |
Basal ganglia | Mean dose (Gy) | 55.9 | 63.4 | 18.3 |
Max dose (Gy) | 6738.0 | 10,231.0 | 5764.0 | |
V20 | 62.3 | 78.7 | 21.4 | |
V30 | 52.7 | 66.2 | 15.4 | |
V50 | 35.9 | 43.7 | 9.3 | |
V60 | 29.9 | 35.1 | 7.7 | |
V80 | 21.2 | 23.6 | 5.5 | |
V100 | 15.8 | 16.7 | 3.9 | |
Hemisphere‡ | Mean dose (Gy) | 14.0 | 21.8 | 17.9 |
Max dose (Gy) | 4484.0 | 10,231.0 | 8864.0 | |
V20 | 19.1 | 39.1 | 18.5 | |
V30 | 12.8 | 22.6 | 16.0 | |
V50 | 6.0 | 8.4 | 12.3 | |
V60 | 4.1 | 5.4 | 10.6 | |
V80 | 2.1 | 2.7 | 7.7 | |
V100 | 1.2 | 1.6 | 5.5 |